ArticleDigestive diseases and sciences2026
Inhibition of PTP1B Through NADH Dehydrogenase Activity Reduces Acute Pancreatic Acinar Cell Pyroptosis by Inhibiting the ROS/TXNIP/NLRP3 Pathway.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aims to investigate the role and regulatory mechanisms of PTP1B in acute pancreatitis.
methodsAn in vitro AP cell model was established using Caerulin (CAE). Cells were subsequently treated with MSI-1436 (PTP1B inhibitor), ruscogenin (TXNIP inhibitor), N-acetyl-L-cysteine (NAC, ROS scavenger), and rotenone (mitochondrial complex I inhibitor), the levels of IL-1β and IL-18 in the cell supernatant were quantified using enzyme-linked immunosorbent assay (ELISA). Propidium iodide (PI) staining was visualized using fluorescence microscopy, and the fluorescence intensity of GSDMD was assessed via immunofluorescence. Western blotting was performed to detect the expression and activation of pro-caspase-1, cleaved-caspase-1, cleaved-caspase-4/5/11, AP-1, ASC, and NLRP3. Mitochondrial membrane potential was assessed using the JC-1 assay, complex I activity was determined with the MitoCheck™ Complex I Activity Assay Kit, and ROS levels were measured using a ROS detection kit.
resultsCAE treatment significantly increased the secretion of inflammatory cytokines IL-1β and IL-18 in pancreatic acinar cells. Expression levels of PTP1B, pyroptosis-related factors-including AP-1, ASC, cleaved-Caspase4, cleaved-Caspase5, cleaved-Caspase11, cleaved-Caspase1, and NLRP3-were significantly upregulated. However, inhibition of PTP1B and TXNIP markedly reduced inflammation and pyroptosis, suggesting that the PTP1B/TXNIP axis mediates CAE-induced cellular injury. Furthermore, suppression of ROS generation and mitochondrial complex I activity also attenuated CAE-induced inflammation and pyroptosis in pancreatic acinar cells.
conclusionTargeting PTP1B mitigates CAE-induced pyroptosis in pancreatic acinar cells by restoring NADH dehydrogenase activity and suppressing ROS/TXNIP/NLRP3 inflammasome activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.